Search Result

Results for "

TXA

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Angiotensin Receptor (3) Angiotensin-converting Enzyme (ACE) (3) Apoptosis (1) Bacterial (3) Calcium Channel (3) Caspase (1) COX (5) Endogenous Metabolite (7) Isotope-Labeled Compounds (3) Leukotriene Receptor (2) Lipoxygenase (2) Na+/K+ ATPase (1) NF-κB (1) p38 MAPK (1) Prostaglandin Receptor (57) Reference Standards (7) ROCK (1)
By Research Areas:	Cancer (11) Cardiovascular Disease (53) Endocrinology (16) Infection (3) Inflammation/Immunology (20) Metabolic Disease (6) Neurological Disease (6)

Inhibitors & Agonists

Biochemical Assay Reagents

Peptides

Natural
Products

Isotope-Labeled Compounds

Antibodies

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-12403

Talfirastide 15+ Cited Publications TXA127; Angiotensin (1-7); Ang-(1-7)	Angiotensin Receptor Angiotensin-converting Enzyme (ACE) Endogenous Metabolite	Cardiovascular Disease Inflammation/Immunology Endocrinology Cancer
Angiotensin 1-7 (Ang-(1-7)) is an endogenous heptapeptide from the renin-angiotensin system (RAS) with a cardioprotective role due to its anti-inflammatory and anti-fibrotic activities in cardiac cells. Angiotensin 1-7 inhibits purified canine ACE activity (IC₅₀=0.65 μM). Angiotensin 1-7 acts as a local synergistic modulator of kinin-induced vasodilation by inhibiting ACE and releasing nitric oxide. Angiotensin 1-7 blocks Ang II-induced smooth muscle cell proliferation and hypertrophy and shows antiangiogenic and growth-inhibitory effects on the endothelium. Angiotensin 1-7 shows anti-inflammatory activity .

HY-108566

U-46619 10+ Cited Publications 9,11-Methanoepoxy PGH2	Prostaglandin Receptor	Cardiovascular Disease
U-46619 (9,11-Methanoepoxy PGH2) is a stable analogue of Thromboxane A2 (HY-113350) (TXA2) and acts as a potent TXA2 (TP) agonist. U-46619 also is a RhoA agonist. U-46619 stimulates the activation of RhoA through TXA2 receptor activation .

HY-N0607

Ginsenoside Ro 1 Publications Verification Polysciasaponin P3; Chikusetsusaponin 5; Chikusetsusaponin V	Calcium Channel Prostaglandin Receptor	Cardiovascular Disease Endocrinology
Ginsenoside Ro (Polysciasaponin P3; Chikusetsusaponin 5; Chikusetsusaponin V) exhibits a Ca ²⁺-antagonistic antiplatelet effect with an IC₅₀ of 155 μM. Ginsenoside Ro reduces the production of *TXA₂* more than it reduces the activities of COX-1 and TXAS.

HY-18763

Indobufen 2 Publications Verification Ibustrin	COX	Cardiovascular Disease
Indobufen is a platelet aggregation inhibitor. Indobufen is a reversible platelet cyclooxygenase (Cox) activity inhibitor. Indobufen suppresses thromboxane A₂ (TxA₂) synthesis. Indobufen down-regulates tissue factor (TF) in monocytes .

HY-153695

TXA707	Bacterial	Infection
TXA707 is an FtsZ-targeting antibacterial agent. TXA707 disrupts bacterial septum formation, induces cell enlargement, causes penicillin-binding protein mislocalization, and triggers cell lysis in Staphylococcus aureus cells. TXA707 can be used for the research of Staphylococcus aureus infections .

HY-B0428

Ozagrel 1 Publications Verification OKY-046	Prostaglandin Receptor	Cardiovascular Disease Neurological Disease Inflammation/Immunology
Ozagrel (OKY-046) is a high selective and orally active thromboxane A₂ (TXA₂) synthase inhibitor with an IC₅₀ of 11 nM. Ozagrel exerts anti-platelet aggregation, vasodilation and anti-inflammatory effects by inhibiting the production of *TXA₂* and increasing the production of prostacyclin (PGI2). Ozagrel can be used for the study of ischemic stroke, asthma and thromboembolic diseases .

HY-B0745

Ramatroban BAY u3405	Prostaglandin Receptor	Inflammation/Immunology Endocrinology Cancer
Ramatroban is a selective thromboxane A₂ (TxA₂, IC₅₀=14 nM) antagonist, which also antagonizes CRTH2 (IC₅₀=113 nM) by inhibiting PGD₂ binding.

HY-16991

Terutroban 1 Publications Verification S-18886	Prostaglandin Receptor	Cardiovascular Disease Metabolic Disease
Terutroban (S-18886) is a selective and orally active thromboxane-prostaglandin (TP) receptor antagonist with an IC₅₀ of 16.4 nM. Terutroban inhibits TXA2 and prostaglandin endoperoxide receptors. Terutroban is a potent antithrombotic agent and possesses anti-atherosclerotic and anti-vasoconstrictor properties .

HY-12403A

Talfirastide acetate 15+ Cited Publications TXA127 acetate; Angiotensin (1-7) acetate; Ang-(1-7) acetate	Angiotensin Receptor Angiotensin-converting Enzyme (ACE) Endogenous Metabolite	Cardiovascular Disease Inflammation/Immunology Endocrinology Cancer
Angiotensin 1-7 (Ang-(1-7)) acetate is an endogenous heptapeptide from the renin-angiotensin system (RAS) with a cardioprotective role due to its anti-inflammatory and anti-fibrotic activities in cardiac cells. Angiotensin 1-7 acetate inhibits purified canine ACE activity (IC₅₀=0.65 μM). Angiotensin 1-7 acetate acts as a local synergistic modulator of kinin-induced vasodilation by inhibiting ACE and releasing nitric oxide. Angiotensin 1-7 acetate blocks Ang II-induced smooth muscle cell proliferation and hypertrophy and shows antiangiogenic and growth-inhibitory effects on the endothelium .

HY-B0428B

Ozagrel hydrochloride 1 Publications Verification OKY-046 hydrochloride	Prostaglandin Receptor	Cardiovascular Disease Neurological Disease Inflammation/Immunology
Ozagrel hydrochloride (OKY-046 hydrochloride) is a high selective and orally active thromboxane A₂ (TXA₂) synthase inhibitor with an IC₅₀ of 11 nM. Ozagrel hydrochloride exerts anti-platelet aggregation, vasodilation and anti-inflammatory effects by inhibiting the production of *TXA₂* and increasing the production of prostacyclin (PGI2). Ozagrel hydrochloride can be used for the study of ischemic stroke, asthma and thromboembolic diseases .

HY-129851

NTP42	Prostaglandin Receptor	Cardiovascular Disease
NTP42 is a *thromboxane A2 (TXA2) receptor* antagonist with an IC₅₀ of 3.278 nM for antagonizing T prostanoid receptor (TP)- mediated [Ca ²⁺] mobilization following stimulation of cells with the alternative TP agonist U46619 . NTP42 can be used for the treatment of pulmonary arterial hypertension (PAH) .

HY-120980

Thromboxane B1 TXB1	Endogenous Metabolite	Cardiovascular Disease
Thromboxane B1 (TXB1) is a stable, inactive endogenous metabolite of Thromboxane A1 (TXA1) .

HY-B0428A

Ozagrel sodium 1 Publications Verification OKY-046 sodium	Prostaglandin Receptor	Cardiovascular Disease Neurological Disease Inflammation/Immunology
Ozagrel sodium (OKY-046 sodium) is a high selective and orally active thromboxane A₂ (TXA₂) synthase inhibitor with an IC₅₀ of 11 nM. Ozagrel sodium exerts anti-platelet aggregation, vasodilation and anti-inflammatory effects by inhibiting the production of *TXA₂* and increasing the production of prostacyclin (PGI2). Ozagrel sodium can be used for the study of ischemic stroke, asthma and thromboembolic diseases .

HY-121018

Daltroban BM-13505; SKF 96148	Prostaglandin Receptor	Cardiovascular Disease
Daltroban (BM-13505) is a selective and specific *thromboxane A2 (TXA2) receptor* antagonist. Daltroban increase intracellular calcium in vascular smooth muscle cells. Daltroban shows protective effect in reperfusion injury .

HY-105218A

Ifetroban sodium 1 Publications Verification BMS-180291 sodium	Prostaglandin Receptor	Cardiovascular Disease Endocrinology Cancer
Ifetroban (BMS-180291) sodium is an orally active antagonist of thromboxane A2 (TXA2) or prostaglandin H2 (PGH2) receptor. Ifetroban sodium shows antiplatelet activity, and inhibits tumor cell migration without affecting cell proliferation. Ifetroban sodium can be used for myocardial ischemia, hypertension, stroke, thrombosis, cardiomyopathy research .

HY-105218

Ifetroban 1 Publications Verification BMS-180291	Prostaglandin Receptor	Cardiovascular Disease Endocrinology Cancer
Ifetroban (BMS-180291) is an orally active antagonist of thromboxane A2 (TXA2) or prostaglandin H2 (PGH2) receptor. Ifetroban shows antiplatelet activity, and inhibits tumor cell migration without affecting cell proliferation. Ifetroban can be used for myocardial ischemia, hypertension, stroke, thrombosis, cardiomyopathy research .

HY-B1735

Picotamide	Prostaglandin Receptor	Cardiovascular Disease
Picotamide is a combined inhibitor of thromboxane A2 (TxA2) synthase and receptor. Picotamide has antiplatelet activity. Picotamide promotes the reduction of microalbuminuria and the inhibition of growth of carotid plaques in diabetes. Picotamide can be used for researching acute or chronic cardiovascular diseases .

HY-150699

TXA6101	Bacterial	Infection
TXA6101 is a bacterial protein FtsZ (filamentous temperature-sensitive protein Z) inhibitor that inhibits bacterial division. TXA6101 has antimicrobial activity against MRSA isolates expressing either the G193D or G196S mutant FtsZ with the MIC value of 1 μg/mL, retains significant activity against the TXA707-resistant FtsZ mutant. TXA6101 can be used as a potential method against Gram-negative bacterial infections .

HY-118044

I-SAP	Prostaglandin Receptor	Cardiovascular Disease
I-SAP is a radioiodinated TXA2/PGH2 receptor antagonist. The bind between I-SAP and the receptors, is inhibited by the histidine modifying reagent diethyl-pyrocarbonate (DEPC) .

HY-16991A

Terutroban sodium 1 Publications Verification S-18886 sodium	Prostaglandin Receptor	Cardiovascular Disease Metabolic Disease
Terutroban (S-18886) sodium is a selective and orally active thromboxane-prostaglandin (TP) receptor antagonist with an IC₅₀ of 16.4 nM. Terutroban sodium inhibits TXA2 and prostaglandin endoperoxide receptors. Terutroban sodium is a potent antithrombotic agent and possesses anti-atherosclerotic and anti-vasoconstrictor properties .

HY-137555

11-dehydro-2,3-dinor Thromboxane B2 11-dehydro-2,3-dinor TXB2	Endogenous Metabolite	Metabolic Disease
11-dehydro-2,3-dinor Thromboxane B2 (11-dehydro-2,3-dinor TXB2) is a metabolite of the TXA2 inactive metabolite TXB2 (Item No. 19030). It is formed from TXB2 by cytosolic aldehyde dehydrogenase (ALDH) and β-oxidation. Levels of 11-dehydro-2,3-dinor TXB2 are increased 5.2-fold in a surgery-induced rat model of tendon overuse.

HY-135447

BM-531	Prostaglandin Receptor	Others
BM-531 is a dual-acting agent for thromboxane receptor (TXA2) antagonism and thromboxane synthase inhibition. BM-531 exerts anti-aggregatory effects on human citrated platelet-rich plasma (PRP), inhibiting Arachidonic acid (HY-109590A)-induced aggregation with an ED₁₀₀ of 0.125 μM and U-46619 (HY-108566)-induced aggregation with an ED₅₀ of 0.482 μM. BM-531 inhibits high-K ⁺-induced contraction of porcine uterine smooth muscle .

HY-165587

BM-573	Prostaglandin Receptor	Cardiovascular Disease
BM-573 is an orally active dual thromboxane A₂ (TXA₂) modulator with an IC₅₀ of 1.3 nM. BM-573 possesses both thromboxane synthase (TxAS) inhibition and thromboxane receptor (TP) antagonistic effects. BM-573 can completely inhibit platelet aggregation induced by Arachidonic acid (HY-109590) or U-46619 (TXA₂ analogues). BM-573 completely blocks the generation of TXB₂ (the stable metabolite of TXA₂) in human platelets and does not inhibit cyclooxygenase (COX-1/COX-2), thus avoiding interference with other prostaglandin synthesis. BM-573 has an inhibitory effect on U-46619-induced contractions in rat gastric fundus smooth muscle (ED₅₀ = 4.2 μM), but has no effect on contractions caused by PGE₂, PGF₂α, or PGI₂. BM-573 can be used in the study of atherosclerosis, myocardial infarction, pulmonary hypertension and shock .

HY-U00072

RS-601	Leukotriene Receptor Prostaglandin Receptor	Inflammation/Immunology Endocrinology
RS-601 is a novel leukotriene D4 (LTD4)/thromboxane A2 (TxA2) dual receptor antagonist, with antiasthmatic activities.

HY-100283

CGS 15435	Prostaglandin Receptor	Inflammation/Immunology Endocrinology
CGS 15435, a potent thromboxane (TxA₂) synthetase inhibitor with an IC₅₀ of 1 nM, has a selectivity for Tx synthetase 100000-fold greater than that for cyclooxygenase, PGI₂ synthetase and lipoxygenase enzymes.

HY-14654B

Aspirin DL-lysine Acetylsalicylic acid DL-lysine; ASA DL-lysine	COX NF-κB p38 MAPK	Cardiovascular Disease Others Inflammation/Immunology
Aspirin DL-lysine (ASA DL-lysine) is a lysine-containing aspirin derivative. Aspirin DL-lysine inhibits cyclooxygenase (COX) in platelets, blocks the synthesis of thromboxane A2 (TXA2), and thus inhibits platelet aggregation and activation. Aspirin DL-lysine can be used to study thrombin generation in patients with unstable angina pectoris .

HY-105866

Wy 27569	Calcium Channel Prostaglandin Receptor	Cardiovascular Disease
Wy 27569 is an orally active vascular selective calcium channel blocker that can effectively lower blood pressure. Wy 27569 is a thromboxane synthase inhibitor that can reshape prostaglandin balance, reduce pro thrombotic *TXA2, and increase anti thrombotic PGI2*. Wy 27569 can be used for research on cardiovascular diseases such as hypertension and angina .

HY-125533

TXA497	Bacterial	Infection
TXA497 is a potent local topical bactericide. TXA497 exerts its bactericidal effect by interfering with the polymerization kinetics of the bacterial cell division protein FtsZ, rather than inhibiting it. TXA497 shows strong activity against various Staphylococcus aureus strains, including MRSA and MSSA, with an MIC value ranging from 1.0 to 2.0 μg/mL. TXA497 skin deposition is concentration-dependent in its formulation, consistent with Fick's first law. TXA497 has limited systemic permeability through the lipid pathway of the stratum corneum and is easily absorbed through this route. TXA497 can be used for research on topical bactericidal agents .

HY-101235

ICI 185282	Prostaglandin Receptor	Cardiovascular Disease Inflammation/Immunology
ICI 185282 is a potent, selective, orally active thromboxane A2 (TXA₂) receptor antagonist. ICI 185282 causes dose-dependent inhibition of U-46619 (HY-108566)-induced platelet aggregation ex-vivo in guinea-pig. ICI 185,282 inhibits bronchospasm induced by U-46619, PGD₂ (HY-101988), PGF_2α (HY-12956), arachidonic acid (HY-109590), LTD₄ and PAF (HY-108635) in vivo. ICI 185282 can be used for bronchial asthma research .

HY-B0149S3

Tranexamic acid-13C2,15N Cyclocapron-¹³C₂,¹⁵N	Isotope-Labeled Compounds	Inflammation/Immunology
Tranexamic acid- ¹³C₂, ¹⁵N (Cyclocapron- ¹³C₂, ¹⁵N) is the ¹³C₂ and ¹⁵N labeled Tranexamic acid. Tranexamic acid is an antifibrinolytic agent that alleviates liver damage and fibrosis in mouse models of chronic bile duct injury .

HY-19129

KT2-962	Prostaglandin Receptor	Cardiovascular Disease
KT2-962 is a thromboxane A2 (TXA2) receptor antagonist and potent hydroxyl radical scavenger (IC₅₀=500 nM). KT2-962 reduces myocardial infarct size and ventricular fibrillation. KT2-962 demonstrates cardioprotective effect in a canine ischemia/reperfusion model. KT2-962 is promising for research of myocardial ischemia-reperfusion injury and TXA2-mediated vascular diseases .

HY-101606

Etersalate Eterylate; Etherylate	Prostaglandin Receptor	Cardiovascular Disease Endocrinology
Etersalate inhibits platelet function and decreases thromboxane A2 (TXA2) levels.

HY-101700

LCB-2853	Prostaglandin Receptor	Cardiovascular Disease
LCB-2853 is an antagonist of *thromboxane A2 (TXA2) receptor*, with antiplatelet and antithrombotic activities.

HY-118920

SQ 26655	Prostaglandin Receptor	Cardiovascular Disease
SQ 26655 is a TxA₂ receptor agonist. SQ 26655 induces human platelet aggregation .

HY-176022

U-46619 serinol amide	Prostaglandin Receptor	Cardiovascular Disease
U-46619 serinol amide is a derivative of U-46619 (HY-108566). U-46619 serinol amide is a stable analog of Thromboxane A2 (HY-113350) (TXA2). U-46619 serinol amide is a potent *TXA2* agonist that can induce platelet shape change and aggregation .

HY-N0607R

Ginsenoside Ro (Standard) Polysciasaponin P3 (Standard); Chikusetsusaponin 5 (Standard); Chikusetsusaponin V (Standard)	Reference Standards Calcium Channel Prostaglandin Receptor	Cardiovascular Disease Endocrinology
Ginsenoside Ro (Standard) is the analytical standard of Ginsenoside Ro. This product is intended for research and analytical applications. Ginsenoside Ro (Polysciasaponin P3; Chikusetsusaponin 5; Chikusetsusaponin V) exhibits a Ca2+-antagonistic antiplatelet effect with an IC50 of 155 μM. Ginsenoside Ro reduces the production of TXA2 more than it reduces the activities of COX-1 and TXAS.

HY-124353

11-Dehydro thromboxane B3 11-Dehydro-TXB3	Endogenous Metabolite	Others
11-Dehydro thromboxane B3 (11-Dehydro-TXB3) is a urinary metabolite of Thromboxane A3 (TXA3) .

HY-169803

L-657926	Prostaglandin Receptor	Cardiovascular Disease
L-657926 is a stereoselective antagonist of the thromboxane A2 (TxA2) receptor, composed of (-)-9-chlorobenzyl-6-fluoro-1,2,3,4-tetrahydrocarbazol-1-yl acetic acid and (+)-9-chlorobenzyl-6-fluoro-1,2,3,4-tetrahydrocarbazol-l-yl acetic acid. The IC₅₀s of (-) and (+) configurations for TxA2 are 0.27 nM and 124 nM, respectively.

HY-121720

L 657925	Prostaglandin Receptor	Cardiovascular Disease
L 657925 is a potent thromboxane A2 (TXA2) antagonist. L 657925 selectively abolishes ONO 11113-evoked transient increment in [Ca2 ²⁺] .

HY-U00355

YM158 free base YM-57158	Leukotriene Receptor Prostaglandin Receptor	Inflammation/Immunology Endocrinology
YM158 free base is a potent and selective LTD₄ and TXA₂ receptor antagonist with pA₂ values of about 8.87 and 8.81, respectively.

HY-12403R

Talfirastide (Standard) TXA127 (Standard); Angiotensin (1-7) (Standard); Ang-(1-7) (Standard)	Angiotensin Receptor Angiotensin-converting Enzyme (ACE) Endogenous Metabolite Reference Standards	Cardiovascular Disease Inflammation/Immunology Endocrinology Cancer
Talfirastide (Standard) is the analytical standard of Talfirastide. This product is intended for research and analytical applications. Angiotensin 1-7 (Ang-(1-7)) is an endogenous heptapeptide from the renin-angiotensin system (RAS) with a cardioprotective role due to its anti-inflammatory and anti-fibrotic activities in cardiac cells. Angiotensin 1-7 inhibits purified canine ACE activity (IC50=0.65 μM). Angiotensin 1-7 acts as a local synergistic modulator of kinin-induced vasodilation by inhibiting ACE and releasing nitric oxide. Angiotensin 1-7 blocks Ang II-induced smooth muscle cell proliferation and hypertrophy and shows antiangiogenic and growth-inhibitory effects on the endothelium. Angiotensin 1-7 shows anti-inflammatory activity .

HY-B0428BR

Ozagrel hydrochloride (Standard) OKY-046 hydrochloride (Standard)	Reference Standards Prostaglandin Receptor	Cardiovascular Disease Neurological Disease Inflammation/Immunology
Ozagrel hydrochloride (Standard) is the analytical reference standard of Ozagrel hydrochloride (HY-B0428B). Ozagrel hydrochloride (OKY-046 hydrochloride) is a high selective and orally active thromboxane A₂ (TXA₂) synthase inhibitor with an IC₅₀ of 11 nM. Ozagrel hydrochloride exerts anti-platelet aggregation, vasodilation and anti-inflammatory effects by inhibiting the production of *TXA₂* and increasing the production of prostacyclin (PGI2). Ozagrel hydrochloride can be used for the study of ischemic stroke, asthma and thromboembolic diseases .

HY-100570

KF15766	Prostaglandin Receptor	Inflammation/Immunology
KF15766 (compd 34E) is an orally active *TXA₂* and H₁ dual antagonist with K_is of 740 and 20 nM. KF15766 can be used for antiallergic research .

HY-19249

Z-335 sodium	Prostaglandin Receptor	Metabolic Disease Inflammation/Immunology
Z-335 sodium is an orally active *thromboxane a₂ (TXA₂)* receptor antagonist, with IC₅₀** values of 29.9 nM and 32.5 nM for human and Guinea pig platelets, respectively .

HY-106066

Dazmegrel UK38485	Prostaglandin Receptor	Cardiovascular Disease
Dazmegrel (UK-38485) is a thromboxane synthetase inhibitor which inhibits Thromboxane A2 (TXA2) synthesis and exhibits antiplatelet vasodilator effects. Dazmegrel can be utilized in thrombosis research .

HY-18763A

Indobufen sodium Ibustrin sodium	COX	Cardiovascular Disease
Indobufen sodium is a platelet aggregation inhibitor. Indobufen sodium is a reversible platelet cyclooxygenase (Cox) activity inhibitor. Indobufen sodium suppresses thromboxane A₂ (TxA₂) synthesis. Indobufen sodium down-regulates tissue factor (TF) in monocytes .

HY-119890

Isbogrel CV-4151	Prostaglandin Receptor	Cardiovascular Disease Cancer
Isbogrel (CV-4151) is a potent selective inhibitor of thromboxane A2 synthase. Isbogrel has oral activity and inhibits blood TXA2 generation with an ID₅₀ value of 0.04 mg/kg .

HY-101236

ICI 192605	Prostaglandin Receptor	Endocrinology
ICI 192605 is a potent *TXA2R* (thromboxane A2 receptor) antagonist as cell signaling prostaglandin. ICI 192605 blocks contraction of isolated guinea pig trachea induced by U-46619 .

HY-116281

ICI D1542	Prostaglandin Receptor	Cardiovascular Disease
ICI D1542 is a selective and potent inhibitor of *thromboxane A2 (TXA2) synthase* and the thromboxane A2 receptor (TP-receptor). ICI D1542 is effective at preventing thrombus formation by redirection of arachidonic acid metabolism .

HY-106080A

Furegrelate sodium U-63557A	Prostaglandin Receptor	Cardiovascular Disease
Furegrelate Sodium (U-63557A) is a potent, orally available, and selective thromboxane synthase inhibitor. Furegrelate Sodium inhibits human platelet microsomal thromboxane A2 (TxA2) synthase with an IC₅₀ of 15 nM. Furegrelate Sodium is being developed as an antiplatelet agent .

Cat. No.	Product Name	Type

HY-135447

BM-531

Biochemical Assay Reagents

BM-531 is a dual-acting agent for thromboxane receptor (TXA2) antagonism and thromboxane synthase inhibition. BM-531 exerts anti-aggregatory effects on human citrated platelet-rich plasma (PRP), inhibiting Arachidonic acid (HY-109590A)-induced aggregation with an ED₁₀₀ of 0.125 μM and U-46619 (HY-108566)-induced aggregation with an ED₅₀ of 0.482 μM. BM-531 inhibits high-K ⁺-induced contraction of porcine uterine smooth muscle .

Cat. No.	Product Name	Target	Research Area

HY-12403

Talfirastide 15+ Cited Publications TXA127; Angiotensin (1-7); Ang-(1-7)	Angiotensin Receptor Angiotensin-converting Enzyme (ACE) Endogenous Metabolite	Cardiovascular Disease Inflammation/Immunology Endocrinology Cancer
Angiotensin 1-7 (Ang-(1-7)) is an endogenous heptapeptide from the renin-angiotensin system (RAS) with a cardioprotective role due to its anti-inflammatory and anti-fibrotic activities in cardiac cells. Angiotensin 1-7 inhibits purified canine ACE activity (IC₅₀=0.65 μM). Angiotensin 1-7 acts as a local synergistic modulator of kinin-induced vasodilation by inhibiting ACE and releasing nitric oxide. Angiotensin 1-7 blocks Ang II-induced smooth muscle cell proliferation and hypertrophy and shows antiangiogenic and growth-inhibitory effects on the endothelium. Angiotensin 1-7 shows anti-inflammatory activity .

HY-12403A

Talfirastide acetate 15+ Cited Publications TXA127 acetate; Angiotensin (1-7) acetate; Ang-(1-7) acetate	Angiotensin Receptor Angiotensin-converting Enzyme (ACE) Endogenous Metabolite	Cardiovascular Disease Inflammation/Immunology Endocrinology Cancer
Angiotensin 1-7 (Ang-(1-7)) acetate is an endogenous heptapeptide from the renin-angiotensin system (RAS) with a cardioprotective role due to its anti-inflammatory and anti-fibrotic activities in cardiac cells. Angiotensin 1-7 acetate inhibits purified canine ACE activity (IC₅₀=0.65 μM). Angiotensin 1-7 acetate acts as a local synergistic modulator of kinin-induced vasodilation by inhibiting ACE and releasing nitric oxide. Angiotensin 1-7 acetate blocks Ang II-induced smooth muscle cell proliferation and hypertrophy and shows antiangiogenic and growth-inhibitory effects on the endothelium .

HY-12403R

Talfirastide (Standard) TXA127 (Standard); Angiotensin (1-7) (Standard); Ang-(1-7) (Standard)	Angiotensin Receptor Angiotensin-converting Enzyme (ACE) Endogenous Metabolite Reference Standards	Cardiovascular Disease Inflammation/Immunology Endocrinology Cancer
Talfirastide (Standard) is the analytical standard of Talfirastide. This product is intended for research and analytical applications. Angiotensin 1-7 (Ang-(1-7)) is an endogenous heptapeptide from the renin-angiotensin system (RAS) with a cardioprotective role due to its anti-inflammatory and anti-fibrotic activities in cardiac cells. Angiotensin 1-7 inhibits purified canine ACE activity (IC50=0.65 μM). Angiotensin 1-7 acts as a local synergistic modulator of kinin-induced vasodilation by inhibiting ACE and releasing nitric oxide. Angiotensin 1-7 blocks Ang II-induced smooth muscle cell proliferation and hypertrophy and shows antiangiogenic and growth-inhibitory effects on the endothelium. Angiotensin 1-7 shows anti-inflammatory activity .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-12403

Talfirastide 15+ Cited Publications TXA127; Angiotensin (1-7); Ang-(1-7)	Natural Products Classification of Application Fields Endogenous metabolite Inflammation/Immunology Disease Research Fields Source Classification	Angiotensin Receptor Angiotensin-converting Enzyme (ACE) Endogenous Metabolite
Angiotensin 1-7 (Ang-(1-7)) is an endogenous heptapeptide from the renin-angiotensin system (RAS) with a cardioprotective role due to its anti-inflammatory and anti-fibrotic activities in cardiac cells. Angiotensin 1-7 inhibits purified canine ACE activity (IC₅₀=0.65 μM). Angiotensin 1-7 acts as a local synergistic modulator of kinin-induced vasodilation by inhibiting ACE and releasing nitric oxide. Angiotensin 1-7 blocks Ang II-induced smooth muscle cell proliferation and hypertrophy and shows antiangiogenic and growth-inhibitory effects on the endothelium. Angiotensin 1-7 shows anti-inflammatory activity .

HY-N0607

Ginsenoside Ro 1 Publications Verification Polysciasaponin P3; Chikusetsusaponin 5; Chikusetsusaponin V	Panax ginseng C. A. Meyer Triterpenes Classification of Application Fields Terpenoids Plants Disease Research Fields Araliaceae Endocrinology Source Classification	Calcium Channel Prostaglandin Receptor
Ginsenoside Ro (Polysciasaponin P3; Chikusetsusaponin 5; Chikusetsusaponin V) exhibits a Ca ²⁺-antagonistic antiplatelet effect with an IC₅₀ of 155 μM. Ginsenoside Ro reduces the production of *TXA₂* more than it reduces the activities of COX-1 and TXAS.

HY-12403A

Talfirastide acetate 15+ Cited Publications TXA127 acetate; Angiotensin (1-7) acetate; Ang-(1-7) acetate	Natural Products Classification of Application Fields Endogenous metabolite Inflammation/Immunology Disease Research Fields Endocrinology Source Classification	Angiotensin Receptor Angiotensin-converting Enzyme (ACE) Endogenous Metabolite
Angiotensin 1-7 (Ang-(1-7)) acetate is an endogenous heptapeptide from the renin-angiotensin system (RAS) with a cardioprotective role due to its anti-inflammatory and anti-fibrotic activities in cardiac cells. Angiotensin 1-7 acetate inhibits purified canine ACE activity (IC₅₀=0.65 μM). Angiotensin 1-7 acetate acts as a local synergistic modulator of kinin-induced vasodilation by inhibiting ACE and releasing nitric oxide. Angiotensin 1-7 acetate blocks Ang II-induced smooth muscle cell proliferation and hypertrophy and shows antiangiogenic and growth-inhibitory effects on the endothelium .

HY-N0607R

Ginsenoside Ro (Standard) Polysciasaponin P3 (Standard); Chikusetsusaponin 5 (Standard); Chikusetsusaponin V (Standard)	Panax ginseng C. A. Meyer Triterpenes Structural Classification Terpenoids Plants Araliaceae Source Classification	Reference Standards Calcium Channel Prostaglandin Receptor
Ginsenoside Ro (Standard) is the analytical standard of Ginsenoside Ro. This product is intended for research and analytical applications. Ginsenoside Ro (Polysciasaponin P3; Chikusetsusaponin 5; Chikusetsusaponin V) exhibits a Ca2+-antagonistic antiplatelet effect with an IC50 of 155 μM. Ginsenoside Ro reduces the production of TXA2 more than it reduces the activities of COX-1 and TXAS.

HY-12403R

Talfirastide (Standard) TXA127 (Standard); Angiotensin (1-7) (Standard); Ang-(1-7) (Standard)	Structural Classification Natural Products Endogenous metabolite Source Classification	Angiotensin Receptor Angiotensin-converting Enzyme (ACE) Endogenous Metabolite Reference Standards
Talfirastide (Standard) is the analytical standard of Talfirastide. This product is intended for research and analytical applications. Angiotensin 1-7 (Ang-(1-7)) is an endogenous heptapeptide from the renin-angiotensin system (RAS) with a cardioprotective role due to its anti-inflammatory and anti-fibrotic activities in cardiac cells. Angiotensin 1-7 inhibits purified canine ACE activity (IC50=0.65 μM). Angiotensin 1-7 acts as a local synergistic modulator of kinin-induced vasodilation by inhibiting ACE and releasing nitric oxide. Angiotensin 1-7 blocks Ang II-induced smooth muscle cell proliferation and hypertrophy and shows antiangiogenic and growth-inhibitory effects on the endothelium. Angiotensin 1-7 shows anti-inflammatory activity .

HY-N16733

Deacetyltanghinin	Apocynaceae Structural Classification Cardiacglycosides Cerbera odollam Gaertn. Plants Steroids Source Classification	Na+/K+ ATPase Apoptosis Caspase Prostaglandin Receptor
Deacetyltanghinin is a selective inhibitor targeting Na ⁺/K ⁺ ATPase, acting through non-covalent binding but is highly cardiotoxic. Deacetyltanghinin inhibits Na ⁺/K ⁺ ATPase activity, induces cancer cell apoptosis (involving caspase pathway activation), and at the same time affect the *TXA2*-PGI2 balance in the rabbit heart. Deacetyltanghinin has significant anti-cancer activity and is mainly used in the research field of targeted therapy of malignant tumors such as breast cancer and lung cancer. At the same time, attention should be paid to the regulation of its cardiotoxicity .

Cat. No.	Product Name	Chemical Structure

HY-B0149S3

Tranexamic acid-13C2,15N
Tranexamic acid- ¹³C₂, ¹⁵N (Cyclocapron- ¹³C₂, ¹⁵N) is the ¹³C₂ and ¹⁵N labeled Tranexamic acid. Tranexamic acid is an antifibrinolytic agent that alleviates liver damage and fibrosis in mouse models of chronic bile duct injury .

HY-B0745S

Ramatroban-d4
Ramatroban-d₄ is deuterium labeled Ramatroban. Ramatroban is a selective thromboxane A2 (TxA2, IC50=14 nM) antagonist, which also antagonizes CRTH2 (IC50=113 nM) by inhibiting PGD2 binding.

HY-18763S

Indobufen-d5
Indobufen-d₅ is deuterium labeled Indobufen. Indobufen is a platelet aggregation inhibitor. Indobufen is a reversible platelet cyclooxygenase (Cox) activity inhibitor. Indobufen suppresses thromboxane A2 (TxA2) synthesis. Indobufen down-regulates tissue factor (TF) in monocytes .

Host:	Rabbit (2)
Reactivity:	Human (2) Mouse (1)
Application:	WB (2)
Isotype:	IgG (2)
Conjugation:	Non-conjugated (2)
Clonality:	Monoclonal (2) Recombinant (2)
Modification:	Unmodified (2)

Cat. No.	Compare	Product Name	Application	Reactivity	Image

HY-P87552

	TXA2R Antibody (YA7236)	WB	Human
	TXA2R Antibody (YA7236) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to TXA2R.

HY-P82925

	Thromboxane A Synthase Antibody (YA2670) TBXAS1; CYP5; CYP5A1; Thromboxane-A synthase; TXA synthase; TXS; Cytochrome P450 5A1	WB	Human, Mouse
	Thromboxane A Synthase Antibody (YA2670) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to Thromboxane A Synthase.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Host
Reactivity
Application
Dilution Ratio
Molecular Weight
Conjugation
Clonality
Immunogen
Appearance
Isotype
Gene ID
SwissProt ID
Purity
Formulation
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

TXA

Inhibitors & Agonists

Biochemical Assay Reagents

Peptides

NaturalProducts

Isotope-Labeled Compounds

Antibodies

Natural
Products